Laparoscopic Devices – Market Insights – United States

The US laparoscopic device market is expected to experience steady growth through 2034, driven by increasing demand for robotic-compatible laparoscopic devices and premium technologies such as energy devices, powered staplers, and 4K video scopes. A generational shift is underway, as more newly trained surgeons are entering the field with a preference for robotic systems due to their precision and ease of use. Although robotic adoption is expanding, its growth is moderated by high capital costs, limited reimbursement, and slower uptake in more complex procedures. Additionally, the rising use of GLP-1 receptor agonists, which reduced the demand for bariatric surgeries, is starting to stabilize. Intuitive Surgical’s da Vinci system continues to dominate the competitive landscape, while competitors like Johnson & Johnson MedTech and Medtronic face adoption challenges despite leveraging bundling strategies and strong laparoscopic portfolios.

This Medtech 360 Report provides comprehensive data and analysis on the state of the market for laparoscopic devices in the US from 2019 through 2034.

Robotic-assisted procedures will account for an increasing proportion of MIS, limiting demand for traditional laparoscopy.

Which procedure types have the highest and lowest laparoscopic technique penetration amid the growing influence of robotic surgery?

Given the rise of robotic surgery, which laparoscopic procedures are still growing, and which ones are nearing saturation?

What technological advancements are companies looking to offer in their laparoscopic surgical robotic devices in the coming years?

How quickly are robotic platforms eroding share from traditional laparoscopic leaders?

What strategies are companies taking to offset the growing dominance of robotic instruments?

Adoption of premium-priced technologies is driving growth in the laparoscopic device market.

Which device segments will show the strongest growth in the US?

Which technologies will see increasing physician adoption during the forecast period?

GLP-1 receptor agonists have been experiencing a meteoric rise in adoption among the US patient population in recent years.

Considering the emerging pharmacological therapies in the pipeline, what is the outlook for bariatric surgery procedures?

How has the rise in GLP-1 receptor agonist prescriptions affected the laparoscopic device market?

Will the laparoscopic device market recover from the increasing use of GLP-1 receptor agonists?

Significant changes were made to CPT reimbursement for anterior abdominal hernia repair.

What were the changes introduced by recent CMS coding updates for anterior abdominal hernia repair procedures?

What are the implications of altered CPT reimbursement on hernia repair procedure volumes?